| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.064 | 0.06 |
| mRNA | SU11274 | CTRPv2 | pan-cancer | AAC | 0.065 | 0.06 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.068 | 0.06 |
| mRNA | ML083 | CTRPv2 | pan-cancer | AAC | -0.071 | 0.06 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.067 | 0.06 |
| mRNA | prima-1 | CTRPv2 | pan-cancer | AAC | -0.057 | 0.07 |
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | 0.063 | 0.07 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.097 | 0.07 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | 0.064 | 0.07 |
| mRNA | vorinostat:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.061 | 0.07 |